PepGen Toekomstige groei

Future criteriumcontroles 0/6

De winst van PepGen zal naar verwachting dalen met 1.8% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 77.7% per jaar. De winst per aandeel zal naar verwachting groeien met 9% per jaar.

Belangrijke informatie

-1.8%

Groei van de winst

9.0%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	77.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Recent updates

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Nov 19

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Aug 06

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Jul 31

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

Sep 07

PepGen GAAP EPS of -$1.23 misses by $0.47

Aug 12

Winst- en omzetgroeiprognoses

NasdaqGS:PEPG - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-113	-129	-147	3
12/31/2025	N/A	-113	-116	-125	4
12/31/2024	N/A	-95	-95	-89	4
9/30/2024	N/A	-87	-83	-82	N/A
6/30/2024	N/A	-89	-75	-75	N/A
3/31/2024	N/A	-80	-78	-76	N/A
12/31/2023	N/A	-79	-72	-69	N/A
9/30/2023	N/A	-74	-66	-63	N/A
6/30/2023	N/A	-69	-71	-67	N/A
3/31/2023	N/A	-67	-66	-62	N/A
12/31/2022	N/A	-69	-63	-59	N/A
9/30/2022	N/A	-61	-55	-52	N/A
6/30/2022	N/A	-51	-41	-39	N/A
3/31/2022	N/A	-39	-34	-32	N/A
12/31/2021	N/A	-27	-23	-23	N/A
9/30/2021	N/A	-23	-17	-17	N/A
6/30/2021	N/A	-15	-10	-10	N/A
3/31/2021	N/A	-10	-4	-4	N/A
12/31/2020	N/A	-4	-2	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PEPG de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PEPG de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PEPG de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat PEPG volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat PEPG volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PEPG naar verwachting over 3 jaar hoog zal zijn

PepGen Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 13% to US$17.00

Price target decreased by 9.3% to US$19.60

Price target decreased by 14% to US$20.00

Recent updates

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Price target decreased by 13% to US$17.00

New major risk - Revenue and earnings growth

PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024

New major risk - Share price stability

PepGen Inc. Appoints Paul Streck as Executive Vice President, Head of Research & Development, Head of Research & Development

Price target decreased by 9.3% to US$19.60

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Chief Medical Officer exercised options and sold US$61k worth of stock

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

PepGen Inc. Announces Positive Data from Low-Dose Cohort of Pgn-Edo51 in Ongoing Connect1-Edo51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Chief Medical Officer exercised options and sold US$72k worth of stock

PepGen Inc. Appoints Afsaneh Mohebbi as SVP, Portfolio and Program Management and Dave Borah as SVP, Investor Relations and Corporate Communications

Chief Medical Officer exercised options and sold US$74k worth of stock

Pepgen Inc. Announces Executive Promotions

Insider notifies of intention to sell stock

The Prognosis For PepGen

Senior Vice President of Chemistry notifies of intention to sell stock

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

PepGen Inc. has completed a Follow-on Equity Offering in the amount of $80.08155 million.

New minor risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 14% to US$20.00

PepGen: Long Road Ahead

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

Pepgen Announces First Patient Dosed in Phase 1 Freedom-Dm1 Clinical Trial of Pgn-Edodm1 for Myotonic Dystrophy Type 1

PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

New major risk - Revenue and earnings growth

PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences

New major risk - Share price stability

New major risk - Revenue and earnings growth

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

New major risk - Share price stability

Pepgen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate A Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1

PepGen Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Key Executive notifies of intention to sell stock

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

PepGen Inc. Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

High number of new and inexperienced directors

PepGen Inc. Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates

PepGen Inc. Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Appoints Habib Dable to Board of Directors

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

PepGen GAAP EPS of -$1.23 misses by $0.47

PepGen Inc. Appoints Caroline Godfrey to Its Scientific Advisory Board

PepGen Inc. has completed an IPO in the amount of $108 million.

High number of new and inexperienced directors

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven